Patents by Inventor Mayela Mendt

Mayela Mendt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240245614
    Abstract: Aspects of the disclosure encompass systems, methods, and compositions for producing exosomes from mesenchymal stem cells and, optionally, loading said exosomes with one or more therapeutic agents. The systems, methods, and compositions may occur in an automated cell expansion system that allows for controllable parameters and from which cells and exosomes may be harvested at one or more times as part of a particular regimen. The exosomes may be loaded with one or more therapeutic agents using electroporation. In specific aspects, the exosomes may be provided to an individual in need thereof, including in some cases where the individual in need thereof is an individual having a medical disorder for which the exosomes would be therapeutic.
    Type: Application
    Filed: May 17, 2022
    Publication date: July 25, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frederick F. LANG, Elizabeth J. SHPALL, Katy REZVANI, Mayela MENDT, Daniel LEDBETTER, Joy GUMIN, Brittany PARKER KERRIGAN, Anwar HOSSAIN, Frederick M. LANG
  • Publication number: 20230390201
    Abstract: Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosome.
    Type: Application
    Filed: August 11, 2023
    Publication date: December 7, 2023
    Inventors: Elizabeth SHPALL, Raghu KALLURI, Katy REZVANI, Mayela MENDT, Valerie LEBLEU, Sushrut KAMERKAR
  • Publication number: 20230383257
    Abstract: Embodiments of the disclosure include systems, methods, and compositions for producing megakaryocytes and platelets for recipient individuals in need thereof. The megakaryocytes and platelets are produced following co-culture of MSCs and CD34+ cells in media comprising stem cell factor, thrombopoietin, and IL-6, and wherein at least the CD34+ cells have a knock-in of HLA-E at the beta-2-microglobulin genomic locus, in specific embodiments. In some cases, ROCK inhibitors are utilized.
    Type: Application
    Filed: October 15, 2021
    Publication date: November 30, 2023
    Inventors: Elizabeth SHPALL, Katy REZVANI, Bijender KUMAR, Mayela MENDT, Vahid AFSHAR-KHARGHAN, Rafet BASAR
  • Patent number: 11766402
    Abstract: Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosomes.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: September 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Elizabeth Shpall, Raghu Kalluri, Katy Rezvani, Mayela Mendt, Valerie Lebleu, Sushrut Kamerkar
  • Publication number: 20230220351
    Abstract: Embodiments of the disclosure encompass systems, methods, and compositions for producing exosomes from primed mesenchymal stem cells that are expanded in the presence of IFN?, TNF?, IL-1?, and IL-17. The systems, methods, and compositions ay occur in an automated cell expansion system that allows for controllable parameters and from which cells and exosomes may be harvested at one or more times as part of a particular regimen. In specific embodiments, the exosomes may be provided to an individual in need thereof, including in some cases when the exosomes comprise one or more therapeutic agents.
    Type: Application
    Filed: June 24, 2021
    Publication date: July 13, 2023
    Inventors: Elizabeth SHPALL, Katy REZVANI, Mayela MENDT
  • Publication number: 20230045174
    Abstract: Embodiments of the disclosure encompass methods and compositions for producing engineered mesenchymal stem/stromal cells (MSCs). The disclosure concerns large-scale processes for producing MSCs that are engineered to have disruption of expression of one or more genes using CRISPR and also express at least one heterologous antigen receptor. Specific embodiments include particular parameters for the process.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 9, 2023
    Inventors: Katy REZVANI, Rafet BASAR, Mayela MENDT, Elizabeth SHPALL
  • Publication number: 20210393698
    Abstract: Provided herein are methods for expanding populations of mesenchymal stromal cells (MSCs) comprising treating a population of MSCs derived from cord tissue with a pre-activation cytokine cocktail.
    Type: Application
    Filed: October 4, 2019
    Publication date: December 23, 2021
    Inventors: Elizabeth Shpall, Katayoun Rezvani, Mayela Mendt
  • Publication number: 20210186877
    Abstract: Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosomes.
    Type: Application
    Filed: November 16, 2018
    Publication date: June 24, 2021
    Inventors: Elizabeth Shpall, Raghu Kalluri, Katy Rezvani, Mayela Mendt, Valerie Lebleu, Sushrut Kamerkar